▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #273 by analyst upside · 2026-08-13
PRQR
ProQR Therapeutics N.V.
Healthcare · Market Cap $262M · P/E 0x
ANALYST PRICE TARGET
+343.5%
implied upside to consensus target
Current Price $1.86
Consensus Target $8.25
Bull Target $12.0
Bear Target $3.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $1.33
52-Week High $3.1
YTD Return -6.5%
FUNDAMENTALS
Market Cap $262M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $14M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.33
52-Week High $3.1
Current Price $1.86
Bear Target $3.0
Bull Target $12.0
● Now $1.86 ● Target $8.25
TRADING DATA
Avg Volume 1.0M
YTD Return -6.5%
Analyst Count 8
Consensus Buy
Upside to Target +343.5%
Last Updated 2026-08-13

ANALYST SUMMARY

ProQR Therapeutics N.V. (PRQR) is currently trading at $1.86 with a Wall Street consensus price target of $8.25, implying potential upside of 343.5% over the next 12 months. 8 analysts currently cover PRQR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $3.0.

PRQR operates in the Healthcare sector with a market capitalisation of $262M. The stock is down 6.5% year-to-date and is currently trading near the lower end of its 52-week range of $1.33 – $3.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PLX +319.8%
Protalix BioTherapeutics, Inc.
$211M · P/E 13.8x · Buy
NAGE +294.9%
Niagen Bioscience, Inc.
$242M · P/E 16.1x · Buy
PALI +421.5%
Palisade Bio, Inc.
$342M · P/E 3.0x · Buy
FBIO +300.0%
Fortress Biotech, Inc.
$91M · P/E 0.8x · Buy
SABS +206.2%
SAB Biotherapeutics, Inc.
$346M · P/E 15.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PRQR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-04-09 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-11-04 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-06-27 40% win rate (10 calls)
JMP Securities reit
Market Outperform → Market Outperform 2025-06-27 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2025-05-13 14% win rate (7 calls)
Evercore ISI Group ● Initiated
Outperform 2025-04-29 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-03-14 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →